Computationally guided high-throughput design of self-assembling drug nanoparticles was written by Reker, Daniel;Rybakova, Yulia;Kirtane, Ameya R.;Cao, Ruonan;Yang, Jee Won;Navamajiti, Natsuda;Gardner, Apolonia;Zhang, Rosanna M.;Esfandiary, Tina;L’Heureux, Johanna;von Erlach, Thomas;Smekalova, Elena M.;Leboeuf, Dominique;Hess, Kaitlyn;Lopes, Aaron;Rogner, Jaimie;Collins, Joy;Tamang, Siddartha M.;Ishida, Keiko;Chamberlain, Paul;Yun, DongSoo;Lytton-Jean, Abigail;Soule, Christian K.;Cheah, Jaime H.;Hayward, Alison M.;Langer, Robert;Traverso, Giovanni. And the article was included in Nature Nanotechnology in 2021.Related Products of 145040-37-5 This article mentions the following:
Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small mol. dyes, which display drug-loading capacities of up to 95%. There is currently no understanding of which of the millions of small-mol. combinations can result in the formation of these nanoparticles. Here we report the integration of machine learning with high-throughput experimentation to enable the rapid and large-scale identification of such nanoformulations. We identified 100 self-assembling drug nanoparticles from 2.1 million pairings, each including one of 788 candidate drugs and one of 2,686 approved excipients. We further characterized two nanoparticles, sorafenib-glycyrrhizin and terbinafine-taurocholic acid both ex vivo and in vivo. We anticipate that our platform can accelerate the development of safer and more efficacious nanoformulations with high drug-loading capacities for a wide range of therapeutics. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Related Products of 145040-37-5).
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Related Products of 145040-37-5
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem